Cyclo Therapeutics- Warrants (14/11/2025) Receivables

As of the most recent data (September 2024), CYTHW shows a receivables of $190K. That compares with $300K in the prior-year period — down 38.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CYTHW's receivables is now $190K (was $300K) — a 38.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Cyclo Therapeutics- Warrants (14/11/2025) is outperforming or lagging.

Tracking CYTHW's receivables over time shows whether Cyclo Therapeutics- Warrants (14/11/2025) is scaling, shrinking, or reshaping that part of the business. The current reading is $190K That compares with $300K in the prior-year period — down 38.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Cyclo Therapeutics- Warrants (14/11/2025)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $190K) with ownership activity and broader fundamentals.

Cyclo Therapeutics- Warrants (14/11/2025)'s receivables is $190K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.